Product information and disease descriptionPlace of product in therapyDisease description
Long-term morbidity
6 evidence topics · 6 sources
Skeletal complications of bone metastases in castration-resistant disease
Skeletal-related events and symptomatic skeletal events as defined for trials
“PCWG2 did not consider skeletal-related events (SREs), which include asymptomatic nonclinical fractures ascertained by serial imaging, clinical pathologic fractures, spinal cord compression, and surgery or radiation therapy to bone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PCWG3 advises reporting SSEs that include only symptomatic events of clear clinical significance, in contrast to SREs, which also include asymptomatic fractures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events without bone-targeted therapy, placebo arm of a randomized trial
“A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time to first skeletal-related event was 321 days for patients who received placebo” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events by type during bone-targeted therapy in metastatic castration-resistant prostate cancer
| First on-study skeletal-related event | Zoledronic acid (n=951) | Denosumab (n=950) |
|---|---|---|
| Total confirmed events | “386 (41%)”View highlighted excerpt for this quote | “341 (36%)”View highlighted excerpt for this quote |
| Radiation to bone | “203 (21%)”View highlighted excerpt for this quote | “177 (19%)”View highlighted excerpt for this quote |
| Pathological fracture | “143 (15%)”View highlighted excerpt for this quote | “137 (14%)”View highlighted excerpt for this quote |
| Spinal cord compression | “36 (4%)”View highlighted excerpt for this quote | “26 (3%)”View highlighted excerpt for this quote |
| Surgery to bone | “4 (<1%)”View highlighted excerpt for this quote | “1 (<1%)”View highlighted excerpt for this quote |
Cumulative incidence of skeletal-related events after diagnosis of bone metastasis, U.S. health systems
“SREs were present at diagnosis of bone metastasis in 22.4, 22.4, and 10.0 % of BC, LC, and PC patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In BC, cumulative incidence of SREs during follow-up was 38.7 % at 6 months, 45.4 % at 12 months, and 54.2 % at 24 months; in LC, it was 41.0, 45.4, and 47.7 %; and in PC, it was 21.5, 30.4, and 41.9 %.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Skeletal-related events and survival, SEER-Medicare men with prostate cancer metastatic to bone
“Among 3,297 men with prostate cancer metastatic to bone, 40% experienced ≥1 SRE (median follow-up, 19 months). Compared with men who remained SRE-free, men with ≥1 SRE had a twofold higher risk for death (HR, 2.29; 95% CI, 2.09–2.51). Pathological fracture was associated with the highest risk for death (HR, 2.77; 95% CI, 2.38–3.23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote